A Phase II, randomised, observer-blind, placebo-controlled, multicentre study to assess the safety, immunogenicity and efficacy of GSK Biologicals Herpes Zoster HZ/su candidate vaccine when administered intramuscularly on a two-dose schedule to adults aged 18 years and older with haematologic malignancies.

Trial Profile

A Phase II, randomised, observer-blind, placebo-controlled, multicentre study to assess the safety, immunogenicity and efficacy of GSK Biologicals Herpes Zoster HZ/su candidate vaccine when administered intramuscularly on a two-dose schedule to adults aged 18 years and older with haematologic malignancies.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Varicella zoster virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 24 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to United Kingdom Clinical Research Network record.
    • 29 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top